AI assistant
Sending…
OnKure Therapeutics, Inc. — Director's Dealing 2021
Apr 8, 2021
34730_dirs_2021-04-08_b064026f-7383-4790-bfab-9478f552139c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-08
Reporting Person: Cardon Lon (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $2.29 | 2029-01-29 | Common Stock (29051) | Direct | |
| Stock option (right to buy) | $4.88 | 2031-01-20 | Common Stock (17877) | Direct |
More from OnKure Therapeutics, Inc.
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Mar 30
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Jan 2
Director's Dealing
2026
Jan 2
Director's Dealing
2025
Dec 23